INTRODUCTION: Amblyopia is commonly associated with squint (strabismus) or refractive errors resulting in different visual inputs to each eye during the sensitive period of visual development (<7-8 years of age). The cumulative incidence is estimated at 2% to 4% in children aged up to 15 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to detect amblyopia early? What are the effects of medical treatments for amblyopia? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations, such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 33 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: active vision therapy; glasses alone or with occlusion; or penalisation to treat amblyopia; and screening to detect amblyopia early.
INTRODUCTION:Amblyopia is commonly associated with squint (strabismus) or refractive errors resulting in different visual inputs to each eye during the sensitive period of visual development (<7-8 years of age). The cumulative incidence is estimated at 2% to 4% in children aged up to 15 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to detect amblyopia early? What are the effects of medical treatments for amblyopia? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations, such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 33 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: active vision therapy; glasses alone or with occlusion; or penalisation to treat amblyopia; and screening to detect amblyopia early.
Authors: Michael X Repka; Raymond T Kraker; Roy W Beck; Jonathan M Holmes; Susan A Cotter; Eileen E Birch; William F Astle; Danielle L Chandler; Joost Felius; Robert W Arnold; D Robbins Tien; Stephen R Glaser Journal: Arch Ophthalmol Date: 2008-08
Authors: Michael X Repka; Roy W Beck; Jonathan M Holmes; Eileen E Birch; Danielle L Chandler; Susan A Cotter; Richard W Hertle; Raymond T Kraker; Pamela S Moke; Graham E Quinn; Mitchell M Scheiman Journal: Arch Ophthalmol Date: 2003-05
Authors: Michael X Repka; Raymond T Kraker; Roy W Beck; Susan A Cotter; Jonathan M Holmes; Robert W Arnold; William F Astle; Nicholas A Sala; D Robbins Tien Journal: Arch Ophthalmol Date: 2009-09
Authors: Mitchell M Scheiman; Richard W Hertle; Raymond T Kraker; Roy W Beck; Eileen E Birch; Joost Felius; Jonathan M Holmes; James Kundart; David G Morrison; Michael X Repka; Susanna M Tamkins Journal: Arch Ophthalmol Date: 2008-12
Authors: Michael X Repka; Raymond T Kraker; Roy W Beck; Eileen Birch; Susan A Cotter; Jonathan M Holmes; Richard W Hertle; Darren L Hoover; Deborah L Klimek; Wendy Marsh-Tootle; Mitchell M Scheiman; Donny W Suh; David R Weakley Journal: J AAPOS Date: 2009-06 Impact factor: 1.220
Authors: Christine Schmucker; Robert Grosselfinger; Rob Riemsma; Gerd Antes; Stefan Lange; Wolf Lagrèze; Jos Kleijnen Journal: BMC Ophthalmol Date: 2009-07-16 Impact factor: 2.209